Bayesian latent time joint mixed effect models for multicohort longitudinal data

Characterization of long-term disease dynamics, from disease-free to end-stage, is integral to understanding the course of neurodegenerative diseases such as Parkinson’s and Alzheimer’s, and ultimately, how best to intervene. Natural history studies typically recruit multiple cohorts at different stages of disease and follow them longitudinally for a relatively short period of time. We propose a latent time joint mixed effects model to characterize long-term disease dynamics using this short-term data. Markov chain Monte Carlo methods are proposed for estimation, model selection, and inference. We apply the model to detailed simulation studies and data from the Alzheimer’s Disease Neuroimaging Initiative.

[1]  Dorota Kurowicka,et al.  Generating random correlation matrices based on vines and extended onion method , 2009, J. Multivar. Anal..

[2]  Sumio Watanabe,et al.  Asymptotic Equivalence of Bayes Cross Validation and Widely Applicable Information Criterion in Singular Learning Theory , 2010, J. Mach. Learn. Res..

[3]  Ranjini Natarajan,et al.  Gibbs Sampling with Diffuse Proper Priors: A Valid Approach to Data-Driven Inference? , 1998 .

[4]  Aki Vehtari,et al.  Understanding predictive information criteria for Bayesian models , 2013, Statistics and Computing.

[5]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[6]  Jiqiang Guo,et al.  Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.

[7]  D. Bates,et al.  Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.

[8]  Alan E. Gelfand,et al.  Model Determination using sampling-based methods , 1996 .

[9]  D. Rubin,et al.  Inference from Iterative Simulation Using Multiple Sequences , 1992 .

[10]  Aki Vehtari,et al.  Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC , 2015, Statistics and Computing.

[11]  Wei Wang,et al.  Identifiability of linear mixed effects models , 2013 .

[12]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[13]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[14]  Shirley Dex,et al.  JR 旅客販売総合システム（マルス）における運用及び管理について , 1991 .

[15]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[16]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[17]  P. Gustafson,et al.  Conservative prior distributions for variance parameters in hierarchical models , 2006 .

[18]  T. Gasser,et al.  Convergence and consistency results for self-modeling nonlinear regression , 1988 .

[19]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[20]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[21]  W. Thompson,et al.  Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOE-ε4 on cerebral cortical thickness in Alzheimer's disease. , 2011, The American journal of psychiatry.

[22]  Hélène Jacqmin-Gadda,et al.  Estimating long-term multivariate progression from short-term data , 2014, Alzheimer's & Dementia.

[23]  A. Gelman.  Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) , 2004 .

[24]  Hong Chang,et al.  Model Determination Using Predictive Distributions with Implementation via Sampling-Based Methods , 1992 .

[25]  Nick C Fox,et al.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.